Frontotemporal neurocognitive disorder (FTD) is one of the leading causes of dementia presenting before age 65, second only to early-onset Alzheimer disease in most clinical series. It is grouped under major or mild neurocognitive disorder in DSM-5-TR with the etiologic specifier frontotemporal lobar degeneration (FTLD), and divided clinically into a behavioral variant (bvFTD) and three primary progressive aphasia (PPA) variants — semantic, nonfluent/agrammatic, and logopenic. The clinical signature is early personality and executive change in bvFTD, or early and disproportionate language breakdown in PPA, against a backdrop of relatively spared memory in the early stages. Diagnosis rests on the Rascovsky (bvFTD) and Gorno-Tempini (PPA) consensus criteria supported by structural and metabolic imaging; FTD is consistently misdiagnosed early as primary psychiatric illness, so a high index of suspicion in atypical mid-life behavioral change is the single most important clinical move. No disease-modifying therapy exists; management centers on symptomatic care, caregiver support, safety planning, and avoidance of harm from antipsychotics and cholinesterase inhibitors used reflexively as if the patient had Alzheimer disease.

FTD accounts for roughly 10–20% of presenile dementias and is the most common neurodegenerative dementia in patients under 60 in most clinical series. Onset typically clusters in the sixth decade, with a long pre-diagnostic interval driven by misattribution to depression, midlife crisis, or personality disorder.

Prevalence and incidence

• Estimated prevalence of FTD spectrum disorders is approximately 15–22 per 100,000 in the 45–65 age band.^[1-2]
• Annual incidence in this age range is roughly 2.7–4.0 per 100,000.^[2]
• After age 65, Alzheimer disease overtakes FTD as the dominant cause of dementia, but FTD continues to occur into the 70s and 80s.^[1,3]

Age and sex

• Mean age of onset is 58 years, with a range from the late 30s to the 80s.^[1,3]
• Sex distribution is roughly equal overall, with a modest male predominance in bvFTD and a possible female predominance in nonfluent/agrammatic PPA in some cohorts.^[3]

Family history and genetics

• Approximately 30–50% of FTD patients have a family history of dementia, psychiatric illness, or motor neuron disease in a first-degree relative.^[3-4]
• Roughly 10–20% of cases follow an autosomal dominant pattern, with the highest yield in bvFTD and FTD with ALS (FTD-ALS).^[4]

Comorbidity

• FTD-ALS overlap occurs in 10–15% of FTD patients and 15% of ALS patients, most strongly linked to C9orf72 expansions.^[4-5]
• Psychiatric comorbidity at diagnosis is common: depressive symptoms, apathy, and prior misdiagnosis of bipolar disorder or schizophrenia are documented in up to half of bvFTD patients.^[6]
• Suicide risk is elevated in early-stage FTD when insight is partially preserved, particularly in PPA.^[6]

FTD is the clinical syndrome; Frontotemporal lobar degeneration (FTLD) is the underlying neuropathology. FTLD is molecularly heterogeneous, with three dominant proteinopathies — tau, TDP-43, and FUS — and a strong, expanding genetic architecture.

Neuropathology — proteinopathy subtypes

• FTLD-tau accounts for roughly 40–45% of cases and includes Pick disease (3R tau), corticobasal degeneration, and progressive supranuclear palsy (both 4R tau).^[7-8]
• FTLD-TDP accounts for roughly 50% and is subtyped A–E based on inclusion morphology, with type A linked to GRN mutations and type B linked to C9orf72 and FTD-ALS.^[7-8]
• FTLD-FUS accounts for the remaining ~5% and is over-represented in young-onset sporadic bvFTD.^[7]

Genetics

• C9orf72 hexanucleotide expansion is the single most common genetic cause, accounting for ~25% of familial FTD and ~40% of familial FTD-ALS.^[4-5]
• GRN (progranulin) and MAPT (microtubule-associated protein tau) mutations are the next most common, each contributing 5–10% of familial cases.^[4]
• Rarer causes include TARDBP, FUS, VCP, CHMP2B, TBK1, and SQSTM1.^[4]
• Apolipoprotein E ε4 is not a strong risk factor for FTD, distinguishing it from Alzheimer disease.^[4]

Neuroanatomy and circuits

• bvFTD targets the Salience network, with early atrophy of the orbitofrontal cortex, anterior cingulate cortex, anterior insula, and frontal pole, plus von Economo neuron loss.^[9-10]
• Semantic variant PPA targets the anterior temporal lobes asymmetrically, usually left-predominant, producing the classic anterior temporal "knife-edge" atrophy.^[11]
• Nonfluent/agrammatic variant PPA targets the left inferior frontal gyrus and dorsal insula (anterior perisylvian network).^[11]
• Logopenic variant PPA targets the left temporoparietal junction; most cases are biologically Alzheimer disease rather than FTLD.^[11-12]

Neurochemistry

• Serotonergic deficits are prominent and provide the rationale for SSRI trials in behavioral symptoms.^[13]
• Dopaminergic deficits in the nigrostriatal pathway underlie parkinsonism in FTD overlap syndromes; the cholinergic system is relatively spared, explaining why cholinesterase inhibitors are generally ineffective or harmful.^[13-14]

DSM-5-TR places FTD within major or mild neurocognitive disorder, with the etiologic subtype "due to frontotemporal lobar degeneration." Specialist neurology and behavioral neurology services additionally use the Rascovsky international consensus criteria for bvFTD and the Gorno-Tempini criteria for PPA, which carry higher specificity and are used in research and tertiary care. DSM-5-TR — major or mild NCD due to FTLD (key features):

• Insidious onset and gradual progression of cognitive impairment that is not better explained by another condition.^[15]
• Either a behavioral variant (prominent decline in social cognition and/or executive abilities with at least three core behavioral symptoms: disinhibition, apathy, loss of sympathy/empathy, perseverative or compulsive behavior, hyperorality/dietary change) or a language variant (prominent decline in language ability — speech production, word-finding, object naming, grammar, or word comprehension).^[15]
• Relative sparing of learning, memory, and perceptual–motor function early in the course.^[15]
• Probable major or mild NCD due to FTLD requires a causative genetic mutation OR evidence of disproportionate frontal and/or temporal involvement on neuroimaging; otherwise the diagnosis is possible.^[15]

Rascovsky criteria — bvFTD (international consensus)

• Possible bvFTD: three of six behavioral/cognitive features present early — disinhibition, apathy/inertia, loss of sympathy/empathy, stereotyped/compulsive behavior, hyperorality/dietary change, and a dysexecutive neuropsychological profile with relative sparing of memory and visuospatial function.^[16]
• Probable bvFTD: meets possible criteria plus functional decline plus characteristic neuroimaging (frontal and/or anterior temporal atrophy on MRI or hypometabolism/hypoperfusion on FDG-PET or SPECT).^[16]
• Definite bvFTD: histopathological confirmation OR a known pathogenic mutation.^[16]

Gorno-Tempini criteria — primary progressive aphasia

• Root diagnosis of PPA requires that language is the most prominent clinical feature and the principal cause of impaired daily functioning, with insidious onset and gradual progression.^[17]
• Semantic variant: impaired single-word comprehension and confrontation naming, with spared repetition and motor speech; left anterior temporal atrophy or hypometabolism.^[17]
• Nonfluent/agrammatic variant: agrammatism and/or effortful, halting speech with apraxia of speech; spared single-word comprehension; left posterior frontoinsular atrophy.^[17]
• Logopenic variant: impaired single-word retrieval and sentence repetition, with phonologic errors and spared grammar and motor speech; left temporoparietal atrophy; majority have underlying Alzheimer pathology.^[12,17]

Specifiers and severity

• DSM-5-TR specifies probable vs. possible, behavioral vs. language variant, and severity (mild, moderate, severe) based on activities of daily living.^[15]
• A "with behavioral disturbance" specifier is added when neuropsychiatric features dominate the picture.^[15]

ICD-11 differences

• ICD-11 classifies FTD under 6D83 "Dementia due to frontotemporal lobar degeneration" within Chapter 06 (Mental, behavioural or neurodevelopmental disorders), with cross-listing to Chapter 08 (Diseases of the nervous system).^[18]
• ICD-11 does not require the formal Rascovsky three-of-six count, but the clinical syndrome is largely concordant with DSM-5-TR.^[18]

FTD's clinical signature is the dissociation between personality, behavior, or language change and the relative preservation of episodic memory and visuospatial function early in the course. Recognizing the prototypical phenotypes — and their atypical variants — is what separates timely diagnosis from years of psychiatric mislabeling.

Behavioral variant FTD

• Disinhibition presents as socially inappropriate behavior, impulsivity, loss of decorum, criminal acts in patients with no prior history, and tactless or sexually inappropriate remarks.^[10,16]
• Apathy and inertia produce withdrawal from work, hobbies, and self-care, often misdiagnosed as depression — but the patient typically reports no subjective sadness, hopelessness, or guilt.^[10]
• Loss of sympathy and empathy manifests as coldness toward family, indifference to others' suffering, and an early erosion of theory of mind.^[10]
• Perseverative, stereotyped, or compulsive behavior ranges from simple motor stereotypies (tapping, rubbing) to complex rituals (hoarding, fixed daily routines, repetitive phrases).^[10,16,23]
• Hyperorality and dietary change includes carbohydrate or sweet cravings, binge eating, oral exploration of inedible objects, and weight gain disproportionate to depression.^[10]
• Dysexecutive cognition with relative sparing of memory and visuospatial skills is the canonical neuropsychological signature.^[16]

Semantic variant PPA

• Anomia and progressive loss of word meaning, with surface dyslexia (irregular words regularized when read aloud — e.g., "yacht" pronounced to rhyme with "matched").^[17]
• Single-word comprehension deficits and impaired object knowledge; the patient may not recognize a familiar object's purpose.^[17]
• Speech remains fluent and grammatically intact; repetition is preserved.^[17]
• Behavioral features (rigidity, food preferences, irritability) often emerge later, blurring the boundary with bvFTD.^[11]

Nonfluent/agrammatic variant PPA

• Effortful, halting speech with phonemic errors and apraxia of speech.^[17]
• Agrammatism in production and comprehension of complex sentences.^[17]
• Single-word comprehension and object knowledge are preserved.^[17]
• Later motor signs include parkinsonism and progressive supranuclear palsy or corticobasal syndrome overlap.^[8,11]

Logopenic variant PPA

• Word-finding pauses and impaired sentence repetition.^[17]
• Phonologic errors without frank agrammatism; single-word comprehension preserved.^[17]
• Biologically Alzheimer disease in most cases — episodic memory deficits and amyloid positivity emerge as the syndrome evolves.^[12]

Prodrome and course

• A pre-diagnostic phase of 3–5 years with subtle personality change, loss of judgment, and occupational decline is common, frequently labeled as depression, midlife crisis, or substance use.^[6,10]
• Disease duration from diagnosis to death averages 6–11 years for bvFTD and PPA, but FTD-ALS shortens median survival to 2–3 years.^[3,5]

Atypical presentations and red flags

• New-onset criminal behavior or hypersexuality in mid-life with no prior psychiatric history.^[6,10]
• Acquired sweet tooth, binge eating, or weight gain in a patient with apathy.^[10]
• Late-onset bipolar-like or schizophrenia-like presentation after age 50, particularly with parkinsonism or motor neuron signs.^[6,19]
• A family history of dementia, ALS, or psychiatric illness with early death.^[4-5]

FTD is differentiated principally from Alzheimer disease, the other primary dementias, and primary psychiatric disorders. Medical and metabolic mimics must be excluded before committing to a neurodegenerative label.

Neurodegenerative dementias

• Alzheimer disease typically begins with episodic memory loss, hippocampal/medial temporal atrophy, and amyloid- and tau-positive biomarkers; behavioral change comes later.^[20]
• Dementia with Lewy bodies features early visual hallucinations, fluctuating cognition, REM sleep behavior disorder, and parkinsonism; antipsychotic hypersensitivity is a clinical red flag.^[21]
• Vascular neurocognitive disorder has stepwise decline, focal deficits, and white-matter or strategic infarcts on imaging.^[20]
• Progressive supranuclear palsy presents with early postural instability, vertical gaze palsy, and axial rigidity; corticobasal syndrome with asymmetric rigidity, dystonia, apraxia, and alien limb.^[8]

Primary psychiatric disorders

• Late-onset major depressive disorder with apathy can closely mimic bvFTD, but reports subjective sadness, anhedonia, guilt, and intact social conduct; antidepressant response and reversibility distinguish it over time.^[6,19,24]
• Bipolar disorder, particularly mania with disinhibition and hyperorality, is the most frequent psychiatric misdiagnosis of bvFTD; FTD lacks classical episodic mood elevation and shows progressive functional decline.^[6,19]
• Late-onset schizophrenia or delusional disorder can resemble C9orf72-related bvFTD presentations with prominent psychosis.^[5,19]
• Obsessive-compulsive disorder may overlap with stereotyped/compulsive behavior in bvFTD; new-onset compulsions after age 50 should raise suspicion for FTD.^[10]

Medical and metabolic mimics

• Thyroid disease (hypothyroidism, less commonly hyperthyroidism) can produce apathy, executive dysfunction, and weight change.
• B12 and folate deficiency, neurosyphilis, HIV-associated neurocognitive disorder, and autoimmune encephalitis (anti-LGI1, anti-NMDA receptor) can mimic rapidly progressive FTD.
• Chronic alcohol use disorder with frontal-executive dysfunction, frontal contusions from prior head injury, and normal-pressure hydrocephalus belong on the differential.
• Sleep-disordered breathing in middle age can produce executive and behavioral changes that reverse with treatment.

Assessment is anchored in collateral history from someone who knew the patient before the change, because the patient's own report frequently understates what has happened. Bedside testing emphasizes executive function and language; episodic memory testing alone will miss bvFTD entirely in the early years. History — what to ask and whom to ask:

• Get a longitudinal narrative from a spouse, adult child, or close colleague describing what is different about the patient over the last 2–5 years, with specific examples.^[19]
• Ask explicitly about disinhibition, apathy, dietary change, hyperorality, repetitive or compulsive behaviors, social-cognitive lapses, and language change; family members underreport these unless prompted.^[15,19]
• Document occupational decline, financial mistakes, legal trouble, and motor-vehicle incidents, which often predate clinical recognition.^[19,49]
• Screen for family history of dementia, ALS, parkinsonism, and psychiatric illness across three generations.^[4]

Mental status and bedside cognitive testing

• The Montreal Cognitive Assessment (MoCA) is more sensitive than the MMSE for the frontal-executive and language deficits of FTD, but both can be near-normal early in bvFTD.^[19,26]
• The Frontal Assessment Battery (FAB) targets executive function across six subtests and is useful at the bedside.^[19]
• For PPA, assess single-word comprehension, object/face recognition, confrontation naming, motor speech, grammar, and repetition; the Boston Naming Test, Pyramids and Palms Trees Test, and a brief connected-speech sample are practical adjuncts.^[15]
• Social cognition testing (faux pas recognition, the Reading the Mind in the Eyes test) is more sensitive than standard cognitive screens for bvFTD and is increasingly recommended.^[27]

Validated rating instruments

• The Frontal Behavioral Inventory (FBI) and the Neuropsychiatric Inventory (NPI) quantify behavioral symptoms and caregiver burden.^[28]
• The Cambridge Behavioural Inventory–Revised (CBI-R) is widely used in FTD research and clinical follow-up.^[19]
• For motor overlap, examine for parkinsonism, vertical gaze palsy, alien limb, asymmetric apraxia, fasciculations, and bulbar signs.^[22]

Neuroimaging

• Structural MRI is the first-line imaging study and may show frontal and anterior temporal atrophy, often asymmetric, with relative sparing of posterior structures early on.^[29]
• FDG-PET shows frontal and anterior temporal hypometabolism and is more sensitive than MRI in early disease.^[29]
• Amyloid PET (or CSF amyloid β42, tau, and phospho-tau) is the single most clinically useful biomarker pair when distinguishing bvFTD from atypical Alzheimer disease, because amyloid is typically negative in FTLD and positive in Alzheimer disease.^[16,29]
• DAT-SPECT helps separate FTD from dementia with Lewy bodies when parkinsonism is present.^[21]

Genetic testing

• Offer genetic counseling and consider testing for C9orf72, MAPT, and GRN in patients with a positive family history, early onset, or FTD-ALS overlap.^[4,30]
• Carriers identified pre-symptomatically should be enrolled in disease-modifying trial registries when available.^[30]

What NOT to order reflexively

• Routine EEG, lumbar puncture for cell counts, and broad autoimmune panels are not indicated in a typical slowly progressive FTD presentation without red flags such as rapid progression, fluctuations, seizures, or focal neurology.^[20,29]
• Avoid repeat MMSE as the sole follow-up measure; it tracks Alzheimer disease far better than it tracks FTD.^[26]

No disease-modifying therapy exists for any FTD subtype, and the agents that anchor Alzheimer disease management — cholinesterase inhibitors and memantine — are unhelpful and sometimes harmful in FTD.^[31-32] Management is symptomatic, multidisciplinary, and weighted heavily toward caregiver support, environmental modification, and safety planning.^[33]

Pharmacotherapy

• SSRIs are the most commonly used class for behavioral symptoms in bvFTD, with limited evidence suggesting reduction in disinhibition, compulsive behaviors, hyperorality, and stereotypies.^[34-35]
  • sertraline 50-200 mg PO QD and citalopram 20 mg PO QD (FDA-recommended maximum in patients over 60 because of QT prolongation) are commonly chosen first; paroxetine 20-40 mg PO QD has trial data but a randomized trial showed cognitive worsening, so it is generally avoided as first-line.^[34-35]
  • trazodone 150-300 mg PO QD showed reduction in NPI scores in a small placebo-controlled crossover trial in bvFTD.^[36]
• Antipsychotics are used cautiously for severe agitation, aggression, or psychosis that endangers the patient or caregivers, but FTD patients are unusually sensitive to extrapyramidal effects.^[37-38]
  • When unavoidable, lower-potency atypicals such as quetiapine 25-150 mg PO QHS are preferred; high-potency typical agents should be avoided.^[37]
  • All antipsychotics carry a black-box warning for increased mortality in elderly patients with dementia, and this risk applies to FTD.^[38]
• Cholinesterase inhibitors (donepezil, rivastigmine, galantamine) are not recommended in FTD; donepezil has been reported to worsen behavioral symptoms in bvFTD in small studies.^[31-32]
• Memantine is not recommended; randomized trials in bvFTD and semantic-variant PPA showed no benefit and a possible signal of cognitive worsening.^[39]
• Stimulants have been explored for apathy in bvFTD with limited short-term data; methylphenidate showed reduction in risk-taking and apathy in small studies but is not a routine recommendation.^[40]

Psychotherapy and behavioral interventions

• Structured behavioral interventions targeting specific symptoms — scheduled toileting for incontinence, distraction techniques for compulsive routines, environmental modification for hyperorality — are first-line for behavioral management.^[33,41]
• Caregiver psychoeducation and skills training reduce caregiver burden and delay institutionalization in FTD cohorts more reliably than any pharmacologic intervention.^[41-42]
• Speech and language therapy is the core intervention in PPA, with strategy training, script training, and augmentative communication devices having modest evidence in semantic and nonfluent variants.^[43]
• Occupational therapy focused on home safety, driving cessation planning, and daily-routine structuring reduces accidents and conflict.^[33]

Neuromodulation

• Repetitive transcranial magnetic stimulation (rTMS) targeting the dorsolateral prefrontal cortex has been studied in small open-label and sham-controlled trials in bvFTD and PPA with mixed and modest results; it is not standard of care.^[44]
• Transcranial direct current stimulation (tDCS) has been studied as an adjunct to speech therapy in nonfluent PPA with limited evidence of short-term naming benefit.^[45]
• ECT has no established role in FTD outside of treatment of severe comorbid depression with appropriate workup; cognitive risks must be weighed carefully.^[46]

Adjunctive and disease-specific care

• Genetic counseling is recommended for any patient with a known pathogenic variant or strong family history, with cascade testing offered to at-risk relatives after counseling.^[30,47]
• Advance care planning should begin early, while decisional capacity for medical and financial decisions is partially preserved, because capacity erodes rapidly in bvFTD.^[48]
• Driving evaluation is mandatory at diagnosis in bvFTD given disinhibition, impaired judgment, and reduced hazard perception; many patients should stop driving at or near diagnosis.^[33,49]
• Disease-modifying trials remain active for genetic FTD, including antisense oligonucleotides targeting C9orf72 and progranulin-raising therapies for GRN mutation carriers; the most advanced progranulin-elevating candidate (latozinemab) failed its phase 3 clinical endpoint in 2025, and no agent has regulatory approval as of this writing.^[50-51]

The evidence base in FTD is dominated by observational cohorts, expert consensus, and small underpowered trials. No intervention has demonstrated disease modification, and most symptomatic recommendations are extrapolated from other dementias or from open-label series specific to FTD.

The harms picture in FTD is shaped by the absence of disease-modifying therapy, the off-label nature of most symptomatic prescribing, and the vulnerability of an older population with prominent behavioral dysregulation. Limitations of the evidence base compound these harms because trial populations are small, heterogeneous, and rarely subtyped pathologically.

Common adverse effects

• SSRIs commonly cause gastrointestinal upset, sexual dysfunction, and hyponatremia, with the latter particularly relevant in older FTD patients.^[35]
• Trazodone causes sedation and orthostatic hypotension, which raises fall risk in disinhibited patients with impaired hazard perception.^[36]
• Speech and language therapy is generally well tolerated, with caregiver and patient frustration the most common limitation.^[43]

Serious or rare adverse effects

• Atypical antipsychotics carry a black-box warning for increased all-cause mortality in older adults with dementia, driven by cerebrovascular events and pneumonia.^[38]
• Antipsychotics also cause extrapyramidal symptoms, falls, sedation, and metabolic effects, all of which are amplified in FTD by underlying motor and frontal pathology.^[37-38]
• Cholinesterase inhibitors have been reported to worsen agitation and disinhibition in bvFTD, providing a clear example of harm from defaulting to Alzheimer-style management.^[32]
• Rare but serious harms in neuromodulation studies include seizure induction with rTMS and skin burns with tDCS at high currents.^[44-45]

Monitoring and discontinuation

• SSRIs require periodic sodium monitoring in older adults, with hyponatremia most likely in the first month of treatment.^[35]
• Antipsychotics require monitoring of metabolic parameters, EKG for QTc, and ongoing reassessment of the lowest effective dose, with planned discontinuation attempts.^[37-38]
• Abrupt discontinuation of SSRIs can cause a discontinuation syndrome that mimics worsening behavioral disturbance in FTD.^[35]

Limitations of the evidence base

• Most FTD trials are small, short, and enroll clinically diagnosed cohorts without pathological confirmation, so subtype-specific signals are diluted.^[33-34]
• Outcome measures are heterogeneous and rarely validated specifically for FTD, complicating cross-trial comparison.^[33]
• Publication bias and industry sponsorship are limited concerns because most agents are generic, but selective reporting of positive open-label series is a real risk.^[34]
• Generalizability to genetic and sporadic FTD across racial, ethnic, and socioeconomic groups is poor; most cohorts are from specialty centers in high-income countries.^[3-4]

FTD intersects with several special-population issues more often than other dementias: younger patients with dependent children, comorbid motor neuron disease, and presymptomatic carriers of pathogenic variants. Each demands a tailored approach.

Younger patients and working-age adults

• Many FTD patients are in the workforce at diagnosis, raising urgent issues of disability determination, financial protection, and capacity for major decisions.^[52]
• Children and adolescents in the household are at developmental risk from a parent's behavioral change and from anticipatory grief, and benefit from age-appropriate disclosure and family support.^[52]
• Sexual disinhibition, financial impulsivity, and traffic violations are common early-disease events that require proactive risk planning rather than reactive crisis management.^[49,52]

FTD-ALS overlap

• Patients with FTD-ALS require coordinated neurology, palliative care, respiratory, and nutrition support, with attention to communication strategies as bulbar symptoms progress.^[5]
• Cognitive and behavioral impairment in ALS shortens survival and complicates decisions about gastrostomy and noninvasive ventilation, making early advance care planning essential.^[5]

Genetic and presymptomatic carriers

• First-degree relatives of patients with known pathogenic variants in C9orf72, GRN, or MAPT should be referred for genetic counseling before any predictive testing.^[4,47]
• Presymptomatic carrier cohorts (GENFI, ARTFL-LEFFTDS) are the basis for current biomarker and prevention trials and offer a structured pathway for at-risk individuals.^[4]

Late-onset and overlap with Alzheimer disease

• After age 70, FTD becomes harder to distinguish from atypical Alzheimer disease, and mixed pathology at autopsy is common.^[1,53]
• CSF and plasma Alzheimer biomarkers (Aβ42/40 ratio, p-tau181, p-tau217) help exclude underlying AD pathology when the phenotype is ambiguous.^[20]

Cultural and access considerations

• Behavioral symptoms in bvFTD are commonly misattributed across cultures to moral failure, family conflict, or possession, delaying diagnosis and intensifying caregiver stigma.^[54]
• Access to subspecialty memory and behavioral neurology services is uneven, and primary care recognition of FTD remains a major bottleneck globally.^[54]

FTD is uniformly progressive and ultimately fatal, with course and survival varying meaningfully by subtype and by the presence of motor features. Functional decline often outpaces measurable cognitive change because the dominant disability is behavioral and executive.

Survival

• Median survival from symptom onset is approximately 6–11 years for bvFTD and PPA subtypes without motor neuron disease.^[55]
• Median survival in FTD-ALS is markedly shorter at approximately 2–3 years from FTD onset, driven by respiratory failure.^[5,55]
• Survival is shorter in patients with early motor features (corticobasal syndrome, progressive supranuclear palsy phenotype) than in pure bvFTD.^[55]

Trajectory by subtype

• bvFTD typically progresses from behavioral disinhibition and apathy through progressive executive impairment, language decline, and eventual mutism and akinesia.^[15,55]
• Semantic variant PPA progresses from anomia and loss of word meaning through prosopagnosia, behavioral features, and eventual bvFTD-like presentation in late disease.^[16]
• Nonfluent/agrammatic PPA progresses through worsening apraxia of speech and mutism, often with corticobasal or PSP-like motor features in the later years.^[16]

Mortality and cause of death

• Most patients die from aspiration pneumonia, complications of immobility, or, in FTD-ALS, respiratory failure.^[55]
• Suicide is overrepresented compared with the general older-adult population and most often occurs early in the course in patients with preserved insight.^[6]

Predictors of faster decline

• Younger age of onset, early motor neuron involvement, and presence of C9orf72 expansion are associated with faster progression in observational cohorts.^[4,55]
• Higher baseline FTLD-CDR sum-of-boxes scores predict shorter time to institutionalization.^[55]

Emergencies in FTD are usually behavioral rather than cognitive: agitation, aggression, wandering, self-harm, and harm to others. The clinical task is to manage acute risk without iatrogenic harm from sedating medications that an FTD brain tolerates poorly.

Acute agitation and aggression

• First-line management is non-pharmacologic: reduce environmental triggers, redirect, ensure caregiver safety, and rule out delirium from infection, pain, or medication change.^[56]
• Short-term trazodone 50 mg PO^[36] or low-dose quetiapine 12.5 mg PO^[37] may be used for severe agitation, with the lowest effective dose and clear stopping criteria.^[37]
• Intramuscular antipsychotics should be reserved for imminent danger and used with the same caution as in any older-adult dementia, recognizing increased mortality risk.^[38]

Suicide risk

• Suicide risk assessment is essential at diagnosis, particularly in PPA and early bvFTD patients with preserved insight, and should be repeated through the early course.^[6]
• Access to firearms, large medication stocks, and vehicles should be restricted early; capacity for these decisions is often impaired in bvFTD before the family recognizes it.^[6,49]

Wandering and elopement

• Wandering with poor route memory is common in mid-stage disease and is a leading cause of injury; environmental modifications, identification bracelets, and locator technology reduce harm.^[56]

Hospitalization criteria

• Inpatient admission is indicated for agitation refractory to outpatient management, suspected delirium superimposed on FTD, suicidality, or caregiver collapse without a safe alternative placement.^[56]
• Geropsychiatric or specialized behavioral neurology units are preferable to general medical or psychiatric wards when available, because of staff familiarity with disinhibition and feeding behaviors.^[56]

The boundaries between FTD subtypes, primary psychiatric disorders, and other neurodegenerative syndromes remain contested, and the regulatory and ethical landscape around genetic testing is evolving rapidly.

Diagnostic boundaries

• The overlap between late-onset behavioral variant FTD and primary psychiatric disorders (especially bipolar disorder and late-onset schizophrenia) is unresolved, with C9orf72 expansions now identified in patients carrying long-standing psychiatric diagnoses.^[4,57]
• The bvFTD phenocopy syndrome — a clinically indistinguishable but non-progressive presentation — remains poorly understood and complicates prognostic counseling.^[58]
• Logopenic PPA is most often Alzheimer pathology rather than FTLD; whether it should remain grouped clinically with the PPAs or reclassified is debated.^[17]

Biomarkers and disease modification

• CSF and plasma neurofilament light chain (NfL) shows promise for distinguishing FTD from primary psychiatric disorders, but cutoffs are not standardized.^[59]
• Tau and TDP-43 PET tracers remain investigational; in vivo distinction of FTLD-tau from FTLD-TDP is not yet clinically reliable.^[60]
• Disease-modifying trials targeting C9orf72 (antisense oligonucleotides) and progranulin (sortilin-blocking antibodies, gene therapy) have not yet succeeded; the phase 3 INFRONT-3 trial of latozinemab (Alector/GSK) in FTD-GRN met its biomarker endpoint of raising plasma progranulin but missed its clinical endpoint (CDR plus NACC FTLD-SB) in 2025, and development was discontinued.^[50-51]

Genetic testing access

• Cascade testing in asymptomatic at-risk relatives raises insurance, employment, and reproductive-counseling concerns that are handled differently across jurisdictions.^[47]
• Direct-to-consumer genetic results increasingly drive unscheduled clinic visits for C9orf72, GRN, and MAPT findings without pretest counseling.^[47]

End-of-life and capacity

• Loss of insight in bvFTD often precedes loss of decision-making capacity by years; the optimal window for advance directives and surrogate-decision-maker designation is contested.^[48]
• Medical aid in dying jurisdictions vary in whether progressive dementia qualifies, and FTD patients with preserved language but impaired judgment present particular challenges to capacity assessment.^[48]

• FTD is among the leading causes of dementia presenting before age 65, alongside early-onset Alzheimer disease, with mean onset around age 58.^[1,3]
• bvFTD requires three of six core features (disinhibition, apathy, loss of empathy, perseverative/compulsive behavior, hyperorality, dysexecutive cognition) per the Rascovsky criteria.^[15]
• The three PPA variants are semantic, nonfluent/agrammatic, and logopenic; logopenic PPA most often reflects underlying Alzheimer pathology, not FTLD.^[12,17]
• Episodic memory and visuospatial function are characteristically spared early in FTD, distinguishing it from Alzheimer disease.^[25]
• C9orf72 hexanucleotide repeat expansion is the most common genetic cause of FTD and FTD-ALS overlap.^[4-5]
• The three major FTLD molecular pathologies are FTLD-tau, FTLD-TDP, and FTLD-FUS, accounting for approximately 45%, 50%, and 5% of cases respectively.^[7-8]
• Frontotemporal atrophy on MRI and frontotemporal hypometabolism on FDG-PET support the diagnosis but cannot fully distinguish FTLD molecular subtypes in vivo.^[29]
• Cholinesterase inhibitors and memantine do not benefit FTD; cholinesterase inhibitors may worsen behavioral symptoms.^[31-32,39]
• SSRIs (sertraline, citalopram; paroxetine has been shown to impair cognition) and trazodone have the best — though still modest — evidence for behavioral symptoms in bvFTD.^[34-36]
• Antipsychotics should be reserved for severe agitation or psychosis; FTD patients are highly sensitive to extrapyramidal effects and carry the dementia black-box mortality risk.^[37-38]
• Median survival from symptom onset is approximately 6–11 years for bvFTD and PPA; FTD-ALS overlap shortens survival to 2–3 years.^[55]
• FTD-ALS overlap should be screened for in every FTD patient by examining for fasciculations, weakness, bulbar signs, and weight loss.^[4-5]
• Genetic counseling is recommended in any patient with FTD and a positive family history of dementia, psychiatric illness, or motor neuron disease.^[47]
• The bvFTD phenocopy syndrome — clinically indistinguishable from bvFTD but non-progressive over years — argues for cautious prognostic counseling early in the course.^[58]
• Driving evaluation is indicated at diagnosis in bvFTD given disinhibition and impaired judgment, often well before global cognitive impairment is severe.^[49]

No external funding. No conflicts of interest declared. Peer-review status: pending.